References

1. McDermott, M. W., Quinones-Hinjosa, A., Bollen, F. W., Larson, D. A., and Prados, M. (2002). Meningiomas. In Brain Cancer (M. Prados, Ed.), pp. 333-364. BC Decker Inc., Hamilton.

2. DeMonte, F., and Al-Mefty, O. (1995). Meningiomas. In Brain Tumors. An Encyclopedic Approach (A. H. Kaye, and E. R., Laws Eds.), Vol. 35, pp. 675-704. Churchill Livingstone, Edinburgh.

3. Bruner, J. M., Tien, R. D., and Enterline, D. S. (1998). Tumors of the meninges and related tissues. In Russel & Rubinstein's Pathology of Tumors of the Nervous System. (D. D. Bigner, R. E. McLendon, and J. M. Bruner Eds.), Vol. 11, 6th ed., pp. 67-139. Arnold, London.

4. Rohinger, M., Sutherland, G. R., Louw, D. F. et al. (1989). Incidence and clinicopathological features of meningioma. J Neurosurg 71, 665-672.

5. Longstreth, S. T., Dennis, L. K., McGuire, V. M., Drangsholt, M. T., and Koepsell, T. D. (1993). Epidemiology of intracranial meningioma. Cancer 72, 639-648.

6. Preston-Martin, S. (1996). Epidemiology of primary CNS neoplasms. Neurol Clin 14, 273-290.

7. Wrensch, M., Minn, Y., Chew, T., Bondy, M., and Berger, M. S. (2002). Epidemiology of primary brain tumors: Current concepts and review of the literature. Neuro-Oncol 4, 278-299.

8. Manfredonia, M. (1973). Tumors of the nervous system in the African in Eritrea (Ethiopia). African J Med Sci 4, 383-387.

9. Ron, E., Modan, B., and Boice, J. D. (1988). Mortality after radiotherapy for ringworm of the scalp. Am J Epidemiol 127, 713-725.

10. Strojan, P., Popovic, M., and Jereb, B. (2000). Secondary intracranial meningiomas after high-dose cranial irradiation: report of five cases and review of the literature. Int J Radiat Oncol Biol Phys 48, 65-73.

11. Annegers, J. F., Laws, E. R., Kurland, L. T. et al. (1979). Head trauma and subsequent brain tumors. Neurosurg 4, 203-206.

12. Bouton, A. H., and Parsons, J. T. (1993). Retroviruses and cancer: Models for cancer in animals and humans. Cancer Investig 11, 70-79.

13. Butel, J. S., and Lednicky, J. A. (1999). Cell and molecular biology of simian virus 40: Implications for human infections and disease. J Natl Cancer Inst 91, 119-134.

14. Weggen, S., Bayer, T. A., von Deimlin, A. et al. (2000). Low frequency of SV40, JC and BK polyomavirus sequences in human medulloblastomas, meningiomas and ependymomas. Brain Pathol 10, 85-92.

15. Schrell, U. M. H., Adams, E. F., Fahlbusch, R. et al. (1990). Hormonal dependency of cerebral meningiomas. J Neurosurg 73, 743-749.

16. Black, P. M. (1997). Hormones, radiosurgery and virtual reality: new aspects of meningioma management. Can J Neurol Sci 24, 302-306.

17. Hsu, D. W., Efird, J. T., and Hedley-White, E. T. (1997). Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 86, 113-120.

18. Perry, A., Cai, D. X., Scheithauer, B. W. et al. (2000). Merlin, DAL-1, and progesterone receptor expression in clinicopatho-logic subsets of meningiomas: a correlative immunohistochem-ical study of 175 cases. J Neuropathol Exp Neurol 59, 872-879.

19. Lambe, M., Coogan, P., and Baron, J. (1997). Reproductive factors and the risk of brain tumors: a population-based study in Sweden. Int J Cancer 72, 389-393.

20. Sanson, M., and Cornu, P. (2000). Biology of meningiomas. Acta Neurochir (Wien) 142, 493-505.

21. Lamszus, K. (2004). Meningioma pathology, genetics, and biology. J Neuropathol Exp Neurol 63, 275-286.

22. Perry, A., Gutmann, D. H., and Reifenberger, G. (2004). Molecular pathogenesis of meningiomas. J Neurooncol 70, 183-202.

23. Maxwell, M., Shih, S. D., Galanopoulos, T., Hedley-White, E. T., and Cosgrove, G. R. (1998). Familial meningioma: Analysis of expression of neurofibromatosis 2 protein Merlin. Report of two cases. J Neurosurg 88, 562-569.

24. Heth, J. A., Kirby, P., and Menezes, A. H. (2000). Intraspinal familial clear cell meningioma in a mother and child. Case report. J Neurosurg 93, 317-321.

25. Collins, V. P., Nordenskjold, M., and Dumanski, J. P. (1990). The molecular genetics of meningiomas. Brain Pathol 1, 19-24.

26. Zang, K. D. (2001). Meningioma: A cytogenetic model of a complex benign human tumor, including data on 394 karyo-typed cases. Cytogenet Cell Genet 93, 207-220.

27. McClatchey, A. I., Saotome, I., Mercer, K. et al. (1998). Mice heterozygous for a mutation at the NF2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev 12, 1121-1133.

28. Kalamarides, M., Niwa-Kawakita, M., Leblois, H. et al. (2002). NF2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 16, 1060-1065.

29. Gutmann, D. H., Sherman, L., Seftor, L., Haipek, C., Lu, K. H., and Hendrix, M. (1999). Increased expression of the NF2 suppressor gene product, merlin, impairs cell motility, adhesion and spreading. Hum Mol Genet 8, 267-276.

30. Huynh, D. P., Mautner, V., Baser, M. E., Stavrou, D., and Pulst, S. M. (1997). Immunohistochemical detection of schwan-nomin and neurofibromin in vestibular schwannomas, ependymomas and meningiomas. J Neuropathol Exp Neurol 56, 382-390.

31. Wellenreuther, R., Kraus, J. A., Lenartz, D. et al. (1995). Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol 146, 827-832.

32. Ueki, K., Wen-Bin, C., Narita, Y., Asai, A., and Kirino, T. (1999). Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas. Cancer Res 59, 5995-5998.

33. Heinrich, B., Hartmann, C., Stemmer-Rachamimov, A. O., Louis, D. N., and MacCollin, M. (2003). Multiple meningiomas: Investigating the molecular basis of sporadic and familial forms. Int J Cancer 103, 483-488.

34. Simon, M., von Deimling, A., Larson, J. J. et al. (1995). Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression. Cancer Res 55, 4696-4701.

35. Bostrom, J., Meyer-Puttlitz, B., Wolter, M. et al. (2001). Alterations of the tumor suppressor genes CDKN2A (p16[INK4a]), p14(ARF), CDKN2B (p15[INK4b]), and CDKN2C (p18[INK4c]) in atypical and anaplastic meningiomas. Am J Pathol 159, 661-669.

36. Carroll, R. S., Black, P. M., Zhang, J. et al. (1997). Expression and activation of epidermal growth factor receptors in meningio-mas. J Neurosurg 87, 315-323.

37. Yang, S. Y., and Xu, G. M. (2000). Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas. J Clin Neurosci 8, 49-53.

38. Bitzer, M., Opitz, H., Popp, J. et al. (1998). Angiogenesis and brain edema in intracraninal meningiomas: Influence of vascular endothelial growth factor. Acta Neurochir (Wien) 140, 333-340.

39. Drevelagas, A., Karkavelas, G., Chourmouzi, D., Boulogianni, G., Petridis, A., and Dimitriadis, A. (2002). Meningeal tumors. In Imaging of Brain Tumors with Histological Correlations (A. Drevelegas, Ed.), pp. 177-214. Springer, Berlin.

40. Nelson, P. K., Setton, A., Choi, I. S., Ransohoff, J., and Berenstein, A. (1994). Current status of interventional neuror-adiology in the management of meningiomas. Neurosurg Clin N Am 5, 235-259.

41. Latchaw, R. E., and Hirsch, W. L. (1991). Computerized tomography of intracranial meningiomas. In Meningiomas (O. Al-Mefty, Ed.), pp. 195-207. Raven Press, New York.

42. Kaplan, R. D., Coons, S., Drayer, B. P. et al. (1992). MR characteristics of meningioma subtypes at 1.5 Tesla. J Comp Assist Tomogr 16, 366-371.

43. De Monte, F. (1995). Current management of meningiomas. Oncology 9, 83-96.

44. Akeyson, E. W., and McCutcheon, I. E. (1996). Management of benign and aggressive intracranial meningiomas. Oncology 10, 747-756.

45. Olivero, S. C., Lister, J. R., and Elwood, P. W. (1995). The natural history and growth rate of asymptomatic meningiomas: a review of 60 patients. J Neurosurg 83, 222-224.

46. Kuratsu, J. I., Kochi, M., and Ushio, Y. (2000). Incidence and clinical features of asymptomatic meningiomas. J Neurosurg 92, 766-770.

47. Dean, B. L., Flom, R. A., Wallace, R. C. et al. (1994). Efficacy of endovascular treatment of meningiomas: evaluation with matched samples. Am J Neruoradiol 15, 1675-1680.

48. Condra, K. S., Buatti, J. M., Mendenhall, W. M. et al. (1997). Benign meningiomas: primary treatment selection affects survival. Int J Radiat Oncol Biol Phys 39, 427-436.

49. Miralbell, R., Linggood, R. M., de la Monte, S. et al. (1992). The role of radiotherapy in the treatment of subtotally resected benign meningiomas. J Neurooncol 13, 157-164.

50. McCarthy, B. J., Davis, F. G., Freels, S. et al. (1998). Factors associated with survival in patients with meningioma. J Neurosurg 88, 831-839.

51. Goldsmith, B. J., Wara, W. M., Wilson, C. B. et al. (1994). Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg 80, 195-201.

52. Stafford, S. L., Pollock, B. E., Foote, R. L. et al. (2001). Meningioma radiosurgery: Tumor control, outcomes, and complications among 190 consecutive patients. Neurosurg 49, 1029-1038.

53. Ojemann, S. G., Sneed, P. K., Larson, D. A., et al. (2000). Radiosurgery for malignant meningioma: results in 22 patients. J Neurosurg 93(Suppl 3), 62-67.

54. Pollock, B. E., Stafford, S. L., Utter, A., Giannini, C., and Schreiner, S. A. (2003). Stereotactic radiosurgery provides equivalent tumor control to simpson grade 1 resection for paitents with small- to medium-size meningiiomas. Int J Radiat Oncol Biol Phys 55, 1000-1005.

55. Kyritsis, A. P. (1996). Chemotherapy for meningiomas. J Neurooncol 29, 269-272.

56. Younis, G. A., Sawaya, R., DeMonte, F., Hess, K. R., Albrecht, S., and Bruner, J. M. (1995). Aggressive meningeal tumors. J Neurosurg 82, 17-27.

57. Steward, D. J., Maroun, J. A., Peterson, E. et al. (1986). Adriamycin in the treatment of malignant meningiomas. In Biology of Brain Tumours (M. D. Walker and D. G. T. Thomas Eds.), pp. 453-455. Martinus Nijhoff, Boston.

58. Bernstein, M., Villamil, A., Davidson, G., and Erlichman, C. (1994). Necrosis in a meningioma following systemic chemotherapy. Case report. J Neurosurg 81, 284-287.

59. Groves, M. D., DeMonte, F., and Yung, W. K. A. (1995). Chemotherapeutic treatment of aggressive meningeal tumors. Skull Base Surgery 5(Suppl 1), 2.

60. Wober-Bingel, C., Wober, C., Marosi, C., and Prayer, D. (1995). Interferon-alpha-2b for meningioma. Lancet 345, 331.

61. Stewart, D. J., Dahrouge, S., Wee, M., Aitken, S., and Hugenholtz, H. (1995). Intraarterial cisplatin plus intravenous doxorubicin for inoperable recurrent meningiomas. J Neurooncol 24, 189-194.

62. Chamberlain, M. C. (1996). Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg 84, 733-736.

63. Kaba, S. E., DeMonte, F., Bruner, J. M. et al. (1997). The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurg 40, 271-275.

64. Bunick, E. M., Mills, L. C., and Rose, L. I. (1978). Association of acromegaly and meningiomas. J Am Med Assoc 240, 1267-1268.

65. Friend, K. E., Radinsky, R., and McCutcheon, I. E. (1999). Growth hormone receptor expression and function in meningiomas: effect of a specific receptor antagonist. J Neurosurg 91, 93-99.

66. McCutcheon, I. E., Flyvbjerg, A., Hill, H. et al. (2001). Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg 94, 487-492.

67. Markwalder, T. M., Seiler, R. W., and Zava, D. T. (1985). Antiestrogenic therapy of meningiomas - a pilot study. Surg Neurol 24, 245-249.

68. Goodwin, J. W., Crowley, J., Eyre, H. J., Stafford, B., Jaeckle, K. A., and Townsend, J. J. (1990). A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a southwest oncology group study. J Neurooncol 15, 75-77.

69. Oura, S., Sakurai, T., Yoshimura, G. et al. (2000). Regression of a presumec meningioma with the antiestrogen agent mepi-tiostane. Case report. J Neurosurg 93, 132-135.

70. Jaaskelainen, J., Laasonen, E., Karkkainen, J., Haltia, M., and Troupp, H. (1986). Hormone treatment of meningiomas: lack of response to medroxyprogesterone acetate (MPA). A pilot study of five cases. Acta Neurochir (Wien) 80, 35-41.

71. Waelti, E. R., and Markwalder, T. M. (1989). Endocrine manipulation of meningiomas with medroxyprogesterone acetate. Effect of MPA on growth of primary meningioma cells in monolayer tissue culture. Surg Neurol 31, 96-100.

72. Grunberg, S. M., and Weiss, M. H. (1990). Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma. J Neurooncol 8, 61-65.

73. Spitz, I. M., and Barding, D. W. (1993). Mifepristone (RU 486) -A modulator of progestin and glucocordticoid action. New Engl J Med 329, 404-412.

74. Olson, J. J., Beck, D. W., Schlechte, J. et al. (1986). Hormonal manipulation of meningiomas in vitro. J Neurosurg 65, 99-107.

75. Olson, J. J., Beck, D. W., Schlechte, J. A. et al. (1987). Effect of the antiprogesterone RU-38486 on meningioma implanted into nude mice. J Neurosurg 66, 584-587.

76. Blankenstein, M. A., van't Verlaat, J. W., and Croughs, R. J. M. (1989). Hormone dependency of meningiomas. Lancet 1, 1381.

77. Grunberg, S. M., Weiss, M. H., Spitz, I. M. et al. (1991). Treatment of unresectable meningiomas with the antiproges-terone agent mifepristone. J Neurosurg 74, 861-866.

78. Lamberts, S. W. J., Tanghe, H. L. J., Avezaat, C. J. J. et al. (1992). Mifepristone (RU 486) treatment of meningiomas. J Neurol Neurosurg Psych 55, 486-490.

79. Grunberg, S. M., Rankin, C., Townsend, J. et al. (2001). Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma. Proc ASCO 20, 56a.

80. Schrell, U. M. H., Rittig, M. G., Koch, U., Marschalek, R., and Anders, M. (1996). Hydroxyurea for treatment of unresectable meningiomas. Lancet 348, 888-889.

81. Schrell, U. M. H., Rittig, M. G., Anders, M. et al. (1997). Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human mening-ioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J Neurosurg 86, 845-852.

82. Schrell, U. M. H., Rittig, M. G., Anders, M. et al. (1997). Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg 86, 840-844.

83. Krakoff, I. H., Brown, N. C., and Reichard, P. (1968). Inhibition of ribonucleoside diphosphate reductase by hydroxyurea. Cancer Res 28, 1559-1565.

84. Newton, H. B., Slivka, M. A., and Stevens, C. (2000). Hydroxyrea chemotherapy for unresectable or residual menin-gioma. J Neurooncol 49, 165-170.

85. Mason, W. P., Gentill, F., Macdonald, D. R., Hariharan, S., Cruz, C. R., and Abrey, L. E. (2002). Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg 97, 341-346.

86. Paus, S., Klockgether, T., Schlegel, U., and Urbach, H. (2003). Meningioma of the optic nerve sheath: treatment with hydroxyurea. J Neurol Neurosurg Psych 74, 1348-1353.

87. Newton, H. B., Scott, S. R., and Volpi, C. (2004). Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. Br J Neurosurg 18, 495-499.

88. Loven, D., Hardoff, R., Sever, Z. B. et al. (2004). Non-resect-able slow-growing meningiomas treated by hydroxyurea. J Neurooncol 67, 221-226.

89. Fuentes, S., Chinot, O., Dufour, H. et al. (2004). Hydroxyurea treatment for unresectable meningioma. Neurochir 50, 461-467.

90. Newton, H. B. (2003). Molecular neuro-oncology and the development of ''targeted'' therapeutic strategies for brain tumors. Part 1 - growth factor and ras signaling pathways. Expert Rev Anticancer Ther 3, 595-614.

91. Newton, H. B. (2004). Molecular neuro-oncology and the development of ''targeted'' therapeutic strategies for brain tumors. Part 2 - PI3K/Akt/PTEN, mTOR, SHH/PTCH, and angiogenesis. Expert Rev Anticancer Ther 4, 105-128.

Meningioma WHO grade I

Meningioma WHO grade III
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment